Q-omics provides the consensus-scored C17orf64 profile across patient tissues and cancer cell-line models. C17orf64 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C17orf64 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, C17orf64 RNA expression shows 8,520 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, LIHC, and KIRP as cancer lineages where C17orf64 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf64 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf64 survival associations across molecular data types. C17orf64 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf64 RNA expression–survival associations across cancer types. High C17orf64 expression shows unfavorable associations in KIRC, LGG and READ, but favorable associations in UCEC, THYM and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C17orf64 RNA expression.
This table summarizes C17orf64 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for C17orf64. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf64 shows lower tumor expression in KICH and BRCA and higher tumor expression in LIHC, KIRC, KIRP and BLCA. The LIHC box plot shows higher C17orf64 RNA expression in tumor versus normal tissue (log2 FC = +0.147, t-test p = .008).
This table shows molecular features associated with C17orf64 in patient tissues and cancer cell lines. In patient samples, C17orf64 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf64 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
